Our mission is to reduce the burden of treatment for patients with ocular diseases through the development of proprietary, injectable products enabling less frequent administration. Our lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. We are also developing new compounds to treat glaucoma and provide neuroprotection when injected twice per year into the subconjunctiva.
|HQ||Redwood City, US||Map|
|Employees (est.) (Oct 2020)||33||(+14%)|
GrayBug total Funding
GrayBug latest funding size
Time since last funding
|a year ago|
|OrbiMed Advisors, Maryland Venture Fund, Clarus Ventures, Hatteras Venture Partners, Deerfield Management, CBC Group, Blackstone Life Sciences|
When was GrayBug founded?
GrayBug was founded in 2011.
Who are GrayBug key executives?
GrayBug's key executives are Frédéric Guerard, Emmett Cunningham and Michael Keyoung.
How many employees does GrayBug have?
GrayBug has 33 employees.
Who are GrayBug competitors?
Competitors of GrayBug include Cell Source, Harbour Antibodies and Rebiotix.
Where is GrayBug headquarters?
GrayBug headquarters is located at 275 Shoreline Dr #450, Redwood City.
Where are GrayBug offices?
GrayBug has offices in Redwood City and Baltimore.
How many offices does GrayBug have?
GrayBug has 2 offices.
Receive alerts for 300+ data fields across thousands of companies